Published in Schizophr Bull on May 03, 2010
Maternal influenza viral infection causes schizophrenia-like alterations of 5-HT₂A and mGlu₂ receptors in the adult offspring. J Neurosci (2011) 1.36
Behavioral, pharmacological, and immunological abnormalities after streptococcal exposure: a novel rat model of Sydenham chorea and related neuropsychiatric disorders. Neuropsychopharmacology (2012) 1.23
Immune system gene dysregulation in autism and schizophrenia. Dev Neurobiol (2012) 1.04
Peripubertal diazepam administration prevents the emergence of dopamine system hyperresponsivity in the MAM developmental disruption model of schizophrenia. Neuropsychopharmacology (2013) 0.96
Viral infection, inflammation and schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry (2012) 0.96
Altered object-in-place recognition memory, prepulse inhibition, and locomotor activity in the offspring of rats exposed to a viral mimetic during pregnancy. Neuroscience (2011) 0.92
Corresponding decrease in neuronal markers signals progressive parvalbumin neuron loss in MAM schizophrenia model. Int J Neuropsychopharmacol (2014) 0.92
Prenatal stress induces schizophrenia-like alterations of serotonin 2A and metabotropic glutamate 2 receptors in the adult offspring: role of maternal immune system. J Neurosci (2013) 0.92
Olanzapine sensitization and clozapine tolerance: from adolescence to adulthood in the conditioned avoidance response model. Neuropsychopharmacology (2012) 0.91
Intake of 7,8-Dihydroxyflavone During Juvenile and Adolescent Stages Prevents Onset of Psychosis in Adult Offspring After Maternal Immune Activation. Sci Rep (2016) 0.90
Altering the course of schizophrenia: progress and perspectives. Nat Rev Drug Discov (2016) 0.88
Olanzapine treatment of adolescent rats causes enduring specific memory impairments and alters cortical development and function. PLoS One (2013) 0.86
Brain enlargement and increased behavioral and cytokine reactivity in infant monkeys following acute prenatal endotoxemia. Behav Brain Res (2010) 0.86
Effects of risperidone and paliperidone pre-treatment on locomotor response following prenatal immune activation. J Psychiatr Res (2011) 0.85
Effect of paliperidone and risperidone on extracellular glutamate in the prefrontal cortex of rats exposed to prenatal immune activation or MK-801. Neurosci Lett (2011) 0.84
Enhancement of social novelty discrimination by positive allosteric modulators at metabotropic glutamate 5 receptors: adolescent administration prevents adult-onset deficits induced by neonatal treatment with phencyclidine. Psychopharmacology (Berl) (2012) 0.81
Long-lasting sensitization induced by repeated risperidone treatment in adolescent Sprague-Dawley rats: a possible D2 receptor mediated phenomenon? Psychopharmacology (Berl) (2013) 0.80
Maternal Immune Activation and Autism Spectrum Disorder: From Rodents to Nonhuman and Human Primates. Biol Psychiatry (2016) 0.80
Long-term impacts of adolescent risperidone treatment on behavioral responsiveness to olanzapine and clozapine in adulthood. Prog Neuropsychopharmacol Biol Psychiatry (2013) 0.79
Effects of prenatal immune activation and peri-adolescent stress on amphetamine-induced conditioned place preference in the rat. Psychopharmacology (Berl) (2012) 0.79
Synergistic Effect between Maternal Infection and Adolescent Cannabinoid Exposure on Serotonin 5HT1A Receptor Binding in the Hippocampus: Testing the "Two Hit" Hypothesis for the Development of Schizophrenia. ISRN Psychiatry (2012) 0.78
Adolescence as a period of vulnerability and intervention in schizophrenia: Insights from the MAM model. Neurosci Biobehav Rev (2016) 0.78
Modulation of schizophrenia-related genes in the forebrain of adolescent and adult rats exposed to maternal immune activation. Schizophr Res (2015) 0.78
Effects of nitric oxide-related compounds in the acute ketamine animal model of schizophrenia. BMC Neurosci (2015) 0.77
Animal models of prenatal immune challenge and their contribution to the study of schizophrenia: a systematic review. Braz J Med Biol Res (2012) 0.77
Amygdala Hyperactivity in MAM Model of Schizophrenia is Normalized by Peripubertal Diazepam Administration. Neuropsychopharmacology (2016) 0.77
Effects of antipsychotics on dentate gyrus stem cell proliferation and survival in animal models: a critical update. Neural Plast (2012) 0.77
Prophylactic valproic acid treatment prevents schizophrenia-related behaviour in Disc1-L100P mutant mice. PLoS One (2012) 0.76
Differential effects of intermittent versus continuous haloperidol treatment throughout adolescence on haloperidol sensitization and social behavior in adulthood. Prog Neuropsychopharmacol Biol Psychiatry (2014) 0.76
Brain in flames - animal models of psychosis: utility and limitations. Neuropsychiatr Dis Treat (2015) 0.76
Antipsychotic-induced sensitization and tolerance: Behavioral characteristics, developmental impacts, and neurobiological mechanisms. J Psychopharmacol (2016) 0.76
Fluoxetine and aripiprazole treatment following prenatal immune activation exert longstanding effects on rat locomotor response. Physiol Behav (2012) 0.76
Asenapine sensitization from adolescence to adulthood and its potential molecular basis. Behav Brain Res (2014) 0.76
Adolescent olanzapine sensitization is correlated with hippocampal stem cell proliferation in a maternal immune activation rat model of schizophrenia. Brain Res (2015) 0.75
The Atypical Antipsychotic Paliperidone Regulates Endogenous Antioxidant/Anti-Inflammatory Pathways in Rat Models of Acute and Chronic Restraint Stress. Neurotherapeutics (2016) 0.75
Tspyl2 Loss-of-Function Causes Neurodevelopmental Brain and Behavior Abnormalities in Mice. Behav Genet (2016) 0.75
Improved Social Interaction, Recognition and Working Memory with Cannabidiol Treatment in a Prenatal Infection (poly I:C) Rat Model. Neuropsychopharmacology (2017) 0.75
Effects of Immune Activation during Early or Late Gestation on N-Methyl-d-Aspartate Receptor Measures in Adult Rat Offspring. Front Psychiatry (2017) 0.75
Early neuromodulation prevents the development of brain and behavioral abnormalities in a rodent model of schizophrenia. Mol Psychiatry (2017) 0.75
The adolescent brain and age-related behavioral manifestations. Neurosci Biobehav Rev (2000) 17.59
Dose translation from animal to human studies revisited. FASEB J (2007) 15.67
Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia. Am J Psychiatry (2003) 10.07
NMDA receptor hypofunction model of schizophrenia. J Psychiatr Res (2000) 4.66
Adult neurogenesis: from precursors to network and physiology. Physiol Rev (2005) 4.25
Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. Am J Psychiatry (2006) 4.18
Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. Arch Gen Psychiatry (2002) 4.06
The developmental role of serotonin: news from mouse molecular genetics. Nat Rev Neurosci (2003) 3.79
Antipsychotic drug effects on brain morphology in first-episode psychosis. Arch Gen Psychiatry (2005) 3.78
Brain volume in first-episode schizophrenia: systematic review and meta-analysis of magnetic resonance imaging studies. Br J Psychiatry (2006) 3.66
Maternal influenza infection causes marked behavioral and pharmacological changes in the offspring. J Neurosci (2003) 3.50
North American Prodrome Longitudinal Study: a collaborative multisite approach to prodromal schizophrenia research. Schizophr Bull (2007) 3.28
Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc Natl Acad Sci U S A (1996) 3.28
Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics (2004) 3.07
The time of prenatal immune challenge determines the specificity of inflammation-mediated brain and behavioral pathology. J Neurosci (2006) 3.03
Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl) (1996) 2.91
Progressive structural brain abnormalities and their relationship to clinical outcome: a longitudinal magnetic resonance imaging study early in schizophrenia. Arch Gen Psychiatry (2003) 2.39
The influence of chronic exposure to antipsychotic medications on brain size before and after tissue fixation: a comparison of haloperidol and olanzapine in macaque monkeys. Neuropsychopharmacology (2005) 2.37
Prenatal infection as a risk factor for schizophrenia. Schizophr Bull (2006) 2.19
Early intervention in psychosis: concepts, evidence and future directions. World Psychiatry (2008) 2.17
Structural brain imaging evidence for multiple pathological processes at different stages of brain development in schizophrenia. Schizophr Bull (2005) 2.13
Grey matter changes over time in high risk subjects developing schizophrenia. Neuroimage (2005) 2.09
Delayed detection of psychosis: causes, consequences, and effect on public health. Am J Psychiatry (2000) 1.98
Dopamine receptor pruning in prefrontal cortex during the periadolescent period in rats. Synapse (2000) 1.98
Pharmacology of risperidone (R 64 766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties. J Pharmacol Exp Ther (1988) 1.97
The early stages of schizophrenia: speculations on pathogenesis, pathophysiology, and therapeutic approaches. Biol Psychiatry (2001) 1.94
Psychobiological risk factors for vulnerability to psychostimulants in human adolescents and animal models. Neurosci Biobehav Rev (1999) 1.90
Immune activation during pregnancy in rats leads to a postpubertal emergence of disrupted latent inhibition, dopaminergic hyperfunction, and altered limbic morphology in the offspring: a novel neurodevelopmental model of schizophrenia. Neuropsychopharmacology (2003) 1.88
Adult brain and behavioral pathological markers of prenatal immune challenge during early/middle and late fetal development in mice. Brain Behav Immun (2007) 1.86
Immune activation during pregnancy in mice leads to dopaminergic hyperfunction and cognitive impairment in the offspring: a neurodevelopmental animal model of schizophrenia. Biol Psychiatry (2005) 1.85
Serotonin research: contributions to understanding psychoses. Trends Pharmacol Sci (2008) 1.75
Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology (1998) 1.70
Towards an immuno-precipitated neurodevelopmental animal model of schizophrenia. Neurosci Biobehav Rev (2005) 1.70
Brain structure and function changes during the development of schizophrenia: the evidence from studies of subjects at increased genetic risk. Schizophr Bull (2008) 1.52
Serotonin and brain development. Int Rev Neurobiol (2004) 1.51
The "two-headed" latent inhibition model of schizophrenia: modeling positive and negative symptoms and their treatment. Psychopharmacology (Berl) (2003) 1.49
Randomized trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome. Biol Psychiatry (2003) 1.49
Prodromal interventions for schizophrenia vulnerability: the risks of being "at risk". Schizophr Res (2005) 1.48
Maternal immune activation leads to behavioral and pharmacological changes in the adult offspring. J Psychiatr Res (2005) 1.47
Neurobiology of dopamine in schizophrenia. Int Rev Neurobiol (2007) 1.44
Gene-environment interaction and covariation in schizophrenia: the role of obstetric complications. Schizophr Bull (2008) 1.44
The neurodevelopmental impact of prenatal infections at different times of pregnancy: the earlier the worse? Neuroscientist (2007) 1.42
Maternal infection leads to abnormal gene regulation and brain atrophy in mouse offspring: implications for genesis of neurodevelopmental disorders. Schizophr Res (2008) 1.42
Serotonin and brain development: role in human developmental diseases. Brain Res Bull (2001) 1.39
A review of stimulant drug research with hyperactive children. J Child Psychol Psychiatry (1977) 1.35
Early intervention for psychosis. Cochrane Database Syst Rev (2006) 1.32
The concept of progressive brain change in schizophrenia: implications for understanding schizophrenia. Schizophr Bull (2008) 1.30
Neuroscience. Maternal effects on schizophrenia risk. Science (2007) 1.29
Recruitment and treatment practices for help-seeking "prodromal" patients. Schizophr Bull (2007) 1.23
Clozapine administration in adolescence prevents postpubertal emergence of brain structural pathology in an animal model of schizophrenia. Biol Psychiatry (2009) 1.22
Prenatal immune activation leads to multiple changes in basal neurotransmitter levels in the adult brain: implications for brain disorders of neurodevelopmental origin such as schizophrenia. Int J Neuropsychopharmacol (2008) 1.21
The New York high risk project to the Hillside recognition and prevention (RAP) program. Am J Med Genet (2002) 1.21
Interaction of antipsychotic drugs with neurotransmitter receptor sites in vitro and in vivo in relation to pharmacological and clinical effects: role of 5HT2 receptors. Psychopharmacology (Berl) (1993) 1.19
Relative prenatal and postnatal maternal contributions to schizophrenia-related neurochemical dysfunction after in utero immune challenge. Neuropsychopharmacology (2007) 1.18
Neurobiological markers of illness onset in psychosis and schizophrenia: The search for a moving target. Neuropsychol Rev (2009) 1.16
Structural cerebral variations as useful endophenotypes in schizophrenia: do they help construct "extended endophenotypes"? Schizophr Bull (2008) 1.12
High-resolution 3D MRI of mouse brain reveals small cerebral structures in vivo. J Neurosci Methods (2002) 1.10
Evaluating early preventive antipsychotic and antidepressant drug treatment in an infection-based neurodevelopmental mouse model of schizophrenia. Schizophr Bull (2008) 1.07
Antipsychotics in the treatment of autism. J Clin Invest (2008) 1.06
Atypical neuroleptics stimulate neurogenesis in adult rat brain. J Neurosci Res (2002) 1.04
Post-pubertal emergence of disrupted latent inhibition following prenatal immune activation. Psychopharmacology (Berl) (2003) 1.03
Schizophrenia: new pathological insights and therapies. Annu Rev Med (2007) 1.02
Preliminary evidence for a modulation of fetal dopaminergic development by maternal immune activation during pregnancy. Neuroscience (2008) 1.02
Neurogenic actions of atypical antipsychotic drugs and therapeutic implications. CNS Drugs (2007) 1.02
MR technology for biological studies in mice. NMR Biomed (2007) 0.99
Volumetric measurement of the hippocampus, the anterior cingulate cortex, and the retrosplenial granular cortex of the rat using structural MRI. Brain Res Brain Res Protoc (2002) 0.99
Neuro-archaeology: pre-symptomatic architecture and signature of neurological disorders. Trends Neurosci (2008) 0.99
Pharmacological intervention in the initial prodromal phase of psychosis. Eur Psychiatry (2005) 0.99
Expression of brain-derived neurotrophic factor mRNA in rat hippocampus after treatment with antipsychotic drugs. J Neurosci Res (2003) 0.98
Dopamine and serotonin levels following prenatal viral infection in mouse--implications for psychiatric disorders such as schizophrenia and autism. Eur Neuropsychopharmacol (2008) 0.98
A 3-year naturalistic study of 53 preschool children with pervasive developmental disorders treated with risperidone. J Clin Psychiatry (2003) 0.98
The effects of antipsychotic treatment on cerebral structure and function in schizophrenia. Int Rev Psychiatry (2007) 0.95
Repeated antipsychotic drug exposure in developing rats: dopamine receptor effects. Synapse (2006) 0.95
Early detection and intervention of psychosis. A review. Nord J Psychiatry (2008) 0.92
Effects of neonatal rat Borna disease virus (BDV) infection on the postnatal development of the brain monoaminergic systems. Brain Res Dev Brain Res (2000) 0.92
Effects of repeated risperidone exposure on serotonin receptor subtypes in developing rats. Eur Neuropsychopharmacol (2009) 0.91
Maternal immune activation in mice delays myelination and axonal development in the hippocampus of the offspring. J Neurosci Res (2008) 0.91
Randomized controlled trial of interventions for young people at ultra-high risk of psychosis: study design and baseline characteristics. Aust N Z J Psychiatry (2009) 0.91
Effects of risperidone on dopamine receptor subtypes in developing rat brain. Eur Neuropsychopharmacol (2006) 0.90
Prevention of schizophrenia: can it be achieved? CNS Drugs (2005) 0.90
Treatment challenges and safety considerations for antipsychotic use in children and adolescents with psychoses. J Clin Psychiatry (2004) 0.88
Targeting information-processing deficit in schizophrenia: a novel approach to psychotherapeutic drug discovery. Trends Pharmacol Sci (2006) 0.87
Risperidone pretreatment prevents elevated locomotor activity following neonatal hippocampal lesions. Neuropsychopharmacology (2006) 0.86
Risperidone and haloperidol promote survival of stem cells in the rat hippocampus. Eur Arch Psychiatry Clin Neurosci (2009) 0.86
Neuroimaging and other neurobiological indices in schizophrenia: relationship to measurement of functional outcome. Br J Psychiatry Suppl (2007) 0.85
Ventricular size mapping in a transgenic model of schizophrenia. Brain Res Dev Brain Res (2005) 0.85
Paradoxical effects of D-amphetamine in infant and adolescent mice: role of gender and environmental risk factors. Neurosci Biobehav Rev (2000) 0.83
Behavioral changes in rats with early ventral hippocampal damage vary with age at damage. Brain Res Dev Brain Res (1997) 0.83
Ethics of early prevention in schizophrenia. Aust N Z J Psychiatry (2000) 0.82
Serotonin and dopamine interactions in psychosis prevention. Prog Brain Res (2008) 0.82
Amelioration of behavioral deficits in a rat model of Huntington's disease by an excitotoxic lesion to the globus pallidus. Exp Neurol (2004) 0.82
Disruption and potentiation of latent inhibition by risperidone: the latent inhibition model of atypical antipsychotic action. Neuropsychopharmacology (2002) 0.82
Latent inhibition in 35-day-old rats is not an "adult" latent inhibition: implications for neurodevelopmental models of schizophrenia. Psychopharmacology (Berl) (2003) 0.80
Fast spin-echo for multiple mouse magnetic resonance phenotyping. Magn Reson Med (2005) 0.80
Isolation-rearing of rats produces deficits as adults in the serotonergic innervation of hippocampus. Peptides (2000) 0.79
Psychiatry. DSM-V at a glance. Science (2010) 0.76
Blood transfusion promotes cancer progression: a critical role for aged erythrocytes. Anesthesiology (2008) 3.32
Immune activation during pregnancy in rats leads to a postpubertal emergence of disrupted latent inhibition, dopaminergic hyperfunction, and altered limbic morphology in the offspring: a novel neurodevelopmental model of schizophrenia. Neuropsychopharmacology (2003) 1.88
Mood disorder susceptibility gene CACNA1C modifies mood-related behaviors in mice and interacts with sex to influence behavior in mice and diagnosis in humans. Biol Psychiatry (2010) 1.70
Maternal immune activation leads to behavioral and pharmacological changes in the adult offspring. J Psychiatr Res (2005) 1.47
CACNA1C (Cav1.2) in the pathophysiology of psychiatric disease. Prog Neurobiol (2012) 1.40
The mouse forced swim test. J Vis Exp (2012) 1.24
Clozapine administration in adolescence prevents postpubertal emergence of brain structural pathology in an animal model of schizophrenia. Biol Psychiatry (2009) 1.22
Modulators of the glycine site on NMDA receptors, D-serine and ALX 5407, display similar beneficial effects to clozapine in mouse models of schizophrenia. Psychopharmacology (Berl) (2005) 1.18
Using the pharmacology of latent inhibition to model domains of pathology in schizophrenia and their treatment. Behav Brain Res (2009) 1.10
Post-pubertal emergence of disrupted latent inhibition following prenatal immune activation. Psychopharmacology (Berl) (2003) 1.03
Procognitive and antipsychotic efficacy of glycine transport 1 inhibitors (GlyT1) in acute and neurodevelopmental models of schizophrenia: latent inhibition studies in the rat. Psychopharmacology (Berl) (2008) 1.02
Effects of risperidone treatment in adolescence on hippocampal neurogenesis, parvalbumin expression, and vascularization following prenatal immune activation in rats. Brain Behav Immun (2011) 0.99
Tracing the development of psychosis and its prevention: what can be learned from animal models. Neuropharmacology (2011) 0.97
Abnormal trajectories of neurodevelopment and behavior following in utero insult in the rat. Biol Psychiatry (2011) 0.96
Latent inhibition is disrupted by nucleus accumbens shell lesion but is abnormally persistent following entire nucleus accumbens lesion: The neural site controlling the expression and disruption of the stimulus preexposure effect. Behav Brain Res (2005) 0.90
Mapping brain regions in which deep brain stimulation affects schizophrenia-like behavior in two rat models of schizophrenia. Brain Stimul (2012) 0.88
Scopolamine induces disruption of latent inhibition which is prevented by antipsychotic drugs and an acetylcholinesterase inhibitor. Neuropsychopharmacology (2006) 0.86
Abnormally persistent latent inhibition induced by lesions to the nucleus accumbens core, basolateral amygdala and orbitofrontal cortex is reversed by clozapine but not by haloperidol. J Psychiatr Res (2006) 0.85
Basolateral amygdala lesions in the rat produce an abnormally persistent latent inhibition with weak preexposure but not with context shift. Behav Brain Res (2005) 0.85
Towards an animal model of an antipsychotic drug-resistant cognitive impairment in schizophrenia: scopolamine induces abnormally persistent latent inhibition, which can be reversed by cognitive enhancers but not by antipsychotic drugs. Int J Neuropsychopharmacol (2008) 0.84
Sex-dependent antipsychotic capacity of 17β-estradiol in the latent inhibition model: a typical antipsychotic drug in both sexes, atypical antipsychotic drug in males. Neuropsychopharmacology (2010) 0.84
Pro-cognitive and antipsychotic efficacy of the alpha7 nicotinic partial agonist SSR180711 in pharmacological and neurodevelopmental latent inhibition models of schizophrenia. Neuropsychopharmacology (2009) 0.83
Ovarian hormones modulate 'compulsive' lever-pressing in female rats. Horm Behav (2008) 0.82
The neuropathological contribution of prenatal inflammation to schizophrenia. Expert Rev Neurother (2011) 0.82
Amelioration of behavioral deficits in a rat model of Huntington's disease by an excitotoxic lesion to the globus pallidus. Exp Neurol (2004) 0.82
Fluctuation of latent inhibition along the estrous cycle in the rat: modeling the cyclicity of symptoms in schizophrenic women? Psychoneuroendocrinology (2008) 0.80
AVE1625, a cannabinoid CB1 receptor antagonist, as a co-treatment with antipsychotics for schizophrenia: improvement in cognitive function and reduction of antipsychotic-side effects in rodents. Psychopharmacology (Berl) (2010) 0.80
The M₁/M₄ preferring agonist xanomeline reverses amphetamine-, MK801- and scopolamine-induced abnormalities of latent inhibition: putative efficacy against positive, negative and cognitive symptoms in schizophrenia. Int J Neuropsychopharmacol (2011) 0.80
Contrasting effects of increased and decreased dopamine transmission on latent inhibition in ovariectomized rats and their modulation by 17beta-estradiol: an animal model of menopausal psychosis? Neuropsychopharmacology (2010) 0.80
Putative cognitive enhancers in preclinical models related to schizophrenia: the search for an elusive target. Pharmacol Biochem Behav (2011) 0.79
Differential role of muscarinic transmission within the entorhinal cortex and basolateral amygdala in the processing of irrelevant stimuli. Neuropsychopharmacology (2010) 0.78
Disruption of latent inhibition induced by ovariectomy can be reversed by estradiol and clozapine as well as by co-administration of haloperidol with estradiol but not by haloperidol alone. Psychopharmacology (Berl) (2009) 0.78
SAR110894, a potent histamine H₃-receptor antagonist, displays procognitive effects in rodents. Pharmacol Biochem Behav (2012) 0.78
Clozapine-induced potentiation of latent inhibition is due to its action in the conditioning stage: implications for the mechanism of action of antipsychotic drugs. Int J Neuropsychopharmacol (1999) 0.77
BioTile, a Perl based tool for the identification of differentially enriched regions in tiling microarray data. BMC Bioinformatics (2013) 0.77
Abnormally rapid reversal learning and reduced response to antipsychotic drugs following ovariectomy in female rats. Psychoneuroendocrinology (2011) 0.76
Long-term functional consequences of quinolinic acid striatal lesions and their alteration following an addition of a globus pallidus lesion assessed using pharmacological magnetic resonance imaging. Exp Neurol (2005) 0.75
Dissociating scopolamine-induced disrupted and persistent latent inhibition: stage-dependent effects of glycine and physostigmine. Psychopharmacology (Berl) (2010) 0.75